Haemonetics Corporation Total Assets
Haemonetics Corporation total assets. Based on the latest financial reports, Haemonetics Corporation (HAE) holds total assets worth $2.40 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Haemonetics Corporation worth for the company's overall valuation and market capitalisation.
Total Assets of Haemonetics Corporation (1992–2026)
Total assets of Haemonetics Corporation from 1992 to 2026. This chart illustrates how Haemonetics Corporation's total assets have evolved over time, based on quarterly financial data. See HAE share price today for real-time trading data and today's change.
Haemonetics Corporation - Asset Composition Analysis
Haemonetics Corporation Total Assets Breakdown (March 2026)
Haemonetics Corporation total assets breakdown as of March 2026. Haemonetics Corporation's total assets of $2.40 Billion consist of 34.9% current assets and 65.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 10.2% |
| Accounts Receivable | $216.85 Million | 9.1% |
| Inventory | $306.37 Million | 12.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $447.65 Million | 18.7% |
| Goodwill | $656.37 Million | 27.4% |
Asset Composition Trend (1992–2026)
This chart illustrates how Haemonetics Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Haemonetics Corporation working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Haemonetics Corporation's current assets represent 34.9% of total assets in 2026, a decrease from 54.2% in 1992.
- Cash Position: Cash and equivalents constituted 10.2% of total assets in 2026, up from 2.0% in 1992.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 45.0% of total assets, an increase from 4.0% in 1992.
- Asset Diversification: The largest asset category is goodwill at 27.4% of total assets.
Haemonetics Corporation Competitors by Total Assets
Key competitors of Haemonetics Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
GN Store Nord
CO:GN
|
Denmark | Dkr29.23 Billion |
|
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A
SHG:688212
|
China | CN¥1.86 Billion |
|
Polynovo Ltd
AU:PNV
|
Australia | AU$123.37 Million |
|
L&C Bio Co. Ltd
KQ:290650
|
Korea | ₩497.94 Billion |
|
VIROMED MEDICAL NA O.N.
XETRA:VME
|
Germany | €13.91 Million |
|
Affluent Medical SAS
PA:AFME
|
France | €59.84 Million |
|
DRGEM Corporation
KQ:263690
|
Korea | ₩131.65 Billion |
Haemonetics Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.95 | 1.62 | 3.00 |
| Quick Ratio | 1.87 | 0.99 | 1.57 |
| Cash Ratio | 0.00 | 0.53 | 0.76 |
| Working Capital | $552.28 Million | $356.86 Million | $456.03 Million |
Haemonetics Corporation - Advanced Valuation Insights
This section examines the relationship between Haemonetics Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.81 |
| Latest Market Cap to Assets Ratio | 1.01 |
| Asset Growth Rate (YoY) | -2.2% |
| Total Assets | $2.40 Billion |
| Market Capitalization | $2.43 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Haemonetics Corporation's assets above their book value (1.01x), reflecting positive investor sentiment about the company's future prospects.
Slight Asset Contraction: Haemonetics Corporation's assets decreased by 2.2% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Haemonetics Corporation (1992–2026)
The table below shows the annual total assets of Haemonetics Corporation from 1992 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-03-31 | $2.40 Billion | -2.24% |
| 2025-03-31 | $2.45 Billion | +11.63% |
| 2024-03-31 | $2.20 Billion | +13.48% |
| 2023-03-31 | $1.93 Billion | +4.04% |
| 2022-03-31 | $1.86 Billion | +2.19% |
| 2021-03-31 | $1.82 Billion | +43.63% |
| 2020-03-31 | $1.27 Billion | -0.60% |
| 2019-03-31 | $1.27 Billion | +3.02% |
| 2018-03-31 | $1.24 Billion | -0.11% |
| 2017-03-31 | $1.24 Billion | -5.95% |
| 2016-03-31 | $1.32 Billion | -11.19% |
| 2015-03-31 | $1.48 Billion | -2.48% |
| 2014-03-31 | $1.52 Billion | +4.03% |
| 2013-03-31 | $1.46 Billion | +60.53% |
| 2012-03-31 | $910.63 Million | +9.28% |
| 2011-03-31 | $833.26 Million | +10.49% |
| 2010-03-31 | $754.14 Million | +16.08% |
| 2009-03-31 | $649.69 Million | +6.69% |
| 2008-03-31 | $608.95 Million | +6.32% |
| 2007-03-31 | $572.74 Million | +4.79% |
| 2006-03-31 | $546.54 Million | +16.84% |
| 2005-03-31 | $467.76 Million | +14.82% |
| 2004-03-31 | $407.39 Million | +13.41% |
| 2003-03-31 | $359.21 Million | -1.57% |
| 2002-03-31 | $364.92 Million | +5.68% |
| 2001-03-31 | $345.31 Million | -1.09% |
| 2000-03-31 | $349.11 Million | -2.05% |
| 1999-03-31 | $356.40 Million | +5.85% |
| 1998-03-31 | $336.70 Million | +4.08% |
| 1997-03-31 | $323.50 Million | +12.40% |
| 1996-03-31 | $287.80 Million | +2.60% |
| 1995-03-31 | $280.50 Million | +21.59% |
| 1994-03-31 | $230.70 Million | +27.95% |
| 1993-03-31 | $180.30 Million | +24.52% |
| 1992-03-31 | $144.80 Million | -- |
About Haemonetics Corporation
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information tech… Read more